BioVersys AG (SWX:BIOV)

BioVersys AG Statistics

Total Valuation

BioVersys AG has a market cap or net worth of CHF 174.86 million. The enterprise value is 114.08 million.

Market Cap	174.86M
Enterprise Value	114.08M

Important Dates

The next confirmed earnings date is Thursday, September 3, 2026.

Earnings Date	Sep 3, 2026
Ex-Dividend Date	n/a

Share Statistics

BioVersys AG has 5.85 million shares outstanding. The number of shares has increased by 68.49% in one year.

Current Share Class	5.85M
Shares Outstanding	5.85M
Shares Change (YoY)	+68.49%
Shares Change (QoQ)	+8.71%
Owned by Insiders (%)	3.13%
Owned by Institutions (%)	10.10%
Float	4.29M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	55.07
PB Ratio	2.92
P/TBV Ratio	2.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-5.23
EV / Sales	35.93
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.15

Financial Position

The company has a current ratio of 10.10, with a Debt / Equity ratio of 0.36.

Current Ratio	10.10
Quick Ratio	9.55
Debt / Equity	0.36
Debt / EBITDA	n/a
Debt / FCF	-0.98
Interest Coverage	-18.54

Financial Efficiency

Return on equity (ROE) is -61.94% and return on invested capital (ROIC) is -22.85%.

Return on Equity (ROE)	-61.94%
Return on Assets (ROA)	-19.87%
Return on Invested Capital (ROIC)	-22.85%
Return on Capital Employed (ROCE)	-24.42%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	96,212
Profits Per Employee	-661,515
Employee Count	33
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

In the past 12 months, BioVersys AG has paid 16,000 in taxes.

Income Tax	16,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.45% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-15.45%
50-Day Moving Average	26.28
200-Day Moving Average	26.83
Relative Strength Index (RSI)	54.72
Average Volume (20 Days)	2,942

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioVersys AG had revenue of CHF 3.18 million and -21.83 million in losses. Loss per share was -3.89.

Revenue	3.18M
Gross Profit	3.18M
Operating Income	-19.96M
Pretax Income	-21.81M
Net Income	-21.83M
EBITDA	-19.89M
EBIT	-19.96M
Loss Per Share	-3.89

Balance Sheet

The company has 82.51 million in cash and 21.73 million in debt, with a net cash position of 60.78 million or 10.39 per share.

Cash & Cash Equivalents	82.51M
Total Debt	21.73M
Net Cash	60.78M
Net Cash Per Share	10.39
Equity (Book Value)	59.81M
Book Value Per Share	10.23
Working Capital	80.98M

Cash Flow

In the last 12 months, operating cash flow was -21.95 million and capital expenditures -216,000, giving a free cash flow of -22.16 million.

Operating Cash Flow	-21.95M
Capital Expenditures	-216,000
Depreciation & Amortization	70,000
Net Borrowing	2.67M
Free Cash Flow	-22.16M
FCF Per Share	-3.79

Margins

Gross Margin	100.00%
Operating Margin	-628.76%
Pretax Margin	-687.06%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BioVersys AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-68.49%
Shareholder Yield	-68.49%
Earnings Yield	-12.48%
FCF Yield	-12.67%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioVersys AG has an Altman Z-Score of 2.34 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.34
Piotroski F-Score	1